Abstract Over the course of the twentieth century, human life expectancy at birth rose in high-income nations by approximately 30 years, largely driven by advances in public health and medicine.

In the twentieth century, human life expectancy rose dramatically. Based on the past three decades of observed mortality in the eight countries with the longest-lived populations and in Hong Kong and the United States, Olshansky et al. propose that, without medical breakthroughs that slow aging, radical lifespan extension is implausible in this century.

A drug used to prevent organ rejection in kidney transplant patients is being touted for potentially slowing down aging. Experts comment on the potential benefits and the need for more research.

Last week we reported that The Cat Health Company had closed its pre-seed round and is now moving towards identifying and developing new therapeutics for age-related diseases in cats. As the pet longevity field continues to gather momentum, The Cat Health Company aims to join companies like Loyal and Arterra at the forefront of this movement. Founded by Alex Bacita and Alex Voda, the Bucharest-based company is not only focused on improving the lifespan of our feline friends but also on enhancing their overall quality of life by targeting the underlying mechanisms of aging.

Longevity. Technology: Pet longevity is becoming a growing area of interest for both researchers and consumers; as owners increasingly seek solutions to extend the healthspan of their pets, demand for scientifically backed innovations has grown, and it is a trend that mirrors the rising popularity of similar human-focused longevity research, signaling a shift in how we approach aging across species.

We sat down with Alex Voda, cofounder of The Cat Health Company, to discuss the future of feline longevity and how TCHC plans to turn cutting-edge research into practical treatments for the cats we cherish.